OPTIC

HALCON OPTIC Honored With Four Awards at NeoCon 2023

Retrieved on: 
Monday, June 19, 2023
Table, Exhibition, Education, Health, Sales, Hip, OPTIC, Interior Design (magazine), Acoustics, Collection, Interior, Neoconservatism, Interior design, Silver

STEWARTVILLE, Minn., June 19, 2023 (GLOBE NEWSWIRE) -- Today HALCON announced its new expansive collection of tables and storage, HALCON OPTIC™, was awarded Best of NeoCon Gold for conference room furniture, and Silver in furniture storage and integrated technology categories as well as an Interior Design HiP award at NeoCon 2023.

Key Points: 
  • STEWARTVILLE, Minn., June 19, 2023 (GLOBE NEWSWIRE) -- Today HALCON announced its new expansive collection of tables and storage, HALCON OPTIC™, was awarded Best of NeoCon Gold for conference room furniture, and Silver in furniture storage and integrated technology categories as well as an Interior Design HiP award at NeoCon 2023.
  • OPTIC is the latest solution in the furniture manufacturer’s extensive portfolio of private and open office and meeting room solutions.
  • “We are honored to again be recognized by the Best of NeoCon jurors and Interior Design Magazine,” said Ben Conway, president of HALCON.
  • A hallmark of the trade show since 1990, Best of NeoCon is the official awards program evaluating outstanding new products from exhibiting companies across a wide range of verticals.

Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting

Retrieved on: 
Monday, June 5, 2023
Health, Hospitals, Clinical Trials, General Health, Pharmaceutical, Optical, ENDO, Teprotumumab, Exophthalmos, CT, Graves' ophthalmopathy, Safety, OPTIC, Epidemiology, FACP, FACE, Convention, Saint Andrew's Society, Medicine, ECNU, National Primate Research Exhibition Hall, Randomness, Endocrine Society, Diagnosis, Patient, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Treatment, Food, Duke University Health System, TED, Pharmaceutical industry

Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the annual meeting of the Endocrine Society (ENDO 2023) in Chicago, June 15-18.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data will be presented at the annual meeting of the Endocrine Society (ENDO 2023) in Chicago, June 15-18.
  • TEPEZZA is the first and only medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of Thyroid Eye Disease (TED) regardless of disease activity or duration.
  • Additionally, two people living with TED will join Malini Gupta, M.D., ECNU, FACE, Director of G2Endo, for a discussion on their journey to diagnosis and experience being treated with TEPEZZA.
  • “The ENDO meeting provides an important opportunity to share results from the TEPEZZA Phase 4 clinical trial, which met its primary endpoint and demonstrated significant proptosis improvement in people who have lived with Thyroid Eye Disease for many years and have low disease activity.”

Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, General Health, Pharmaceutical, Health, Safety, Refractory, Science, Translational research, Update, Myeloproliferative neoplasm, Myelodysplastic syndrome, ALK, Center for International Blood and Marrow Transplant Research, Activin and inhibin, DLBCL, European Hematology Association, Research, Polycythemia vera, Combination therapy, S110, Chronic lymphocytic leukemia, Abstract, Combination, Chronic myelogenous leukemia, Cytokine release syndrome, ALL, CRS, Relapse, OPTIC, Lymphoma, MOST, Cancer, Diffuse large B-cell lymphoma, Neoplasm, ALK2, Abstract (summary), CML, PV, ASCO, BET, American Society of Clinical Oncology, EHA, Annual general meeting, Anemia, Society, Pharmaceutical industry, Communications satellite, Allotransplantation, Hydroxycarbamide, Primary myelofibrosis, Patient

ET)

Key Points: 
  • ET)
    Phase 1b, Open-Label Study of Add-On Therapy with CK0804 in Participants with Myelofibrosis, with Suboptimal Response to Ruxolitinib (Abstract #TPS7087.
  • ET)1
    A Phase 1/2 Study of Retifanlimab (INCMGA00012, Anti–PD-1), INCAGN02385 (Anti–LAG-3), and INCAGN02390 (Anti–TIM-3) Combination Therapy in Patients (Pts) with Advanced Solid Tumors (Abstract #2599.
  • ET)
    Abstracts are available on the EHA2023 Congress platform and accessible for on-demand viewing until August 15, 2023.
  • ET)5
    For full session details and data presentation listings, please see the ASCO ( https://conferences.asco.org ) and EHA2023 ( https://ehaweb.org/congress ) online programs.

Adverum Biotechnologies Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
ARVO, CFI, Adverum Biotechnologies, Vance DeGeneres, Doctor of Pharmacy, Gene, Anticipation, AMD, OPTIC, European Medicines Agency, NAMD, Complement, Geographic atrophy, Research, GA, PRIME, IVT, Incidence, Investment, Primate, Hearing, Annual general meeting, Cell, Complement factor I, United Kingdom, Diagnosis, Association for Research in Vision and Ophthalmology, Innovation, FDA, United, Medicines and Healthcare products Regulatory Agency, Safety, Society, Three Months, Disease, Pharmaceutical industry, Vaccine, Cryptocurrency, Ophthalmology

REDWOOD CITY, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD).

Key Points: 
  • We are on track to finish enrolling the study in the second half of 2023,” said Star Seyedkazemi, PharmD, chief development officer of Adverum Biotechnologies.
  • “We plan to provide interim datasets for a percentage of participants at 14 weeks, including aflibercept protein levels, in the third quarter of 2023, as well as preliminary efficacy and safety data in the fourth quarter of 2023.
  • Stock-based compensation expense included in research and development expenses was $1.4 million for the first quarter of 2023.
  • Stock-based compensation expense included in general and administrative expenses was $3.2 million for the first quarter of 2023.

Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD

Retrieved on: 
Tuesday, April 18, 2023
Ministry of National Health Services, Regulation and Coordination, Adverum Biotechnologies, Doctor of Pharmacy, Anti-VEGF, National Health Service, AMD, OPTIC, Eye, LUNA, PRIME, EMA, Patient, United Kingdom, European Medicines Agency, United, National Institute for Health and Care Excellence, Medicines and Healthcare products Regulatory Agency, Innovation, NHS, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Safety, Fast track (FDA), NICE, Food, Caregiver, MHRA, Pharmaceutical industry

REDWOOD CITY, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ixo-vec (ixoberogene soroparvovec), an investigational gene therapy for the treatment of wet AMD, an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP). The Innovation Passport is the first step in the ILAP process, triggering the MHRA and its partner agencies, including the National Institute for Health and Care Excellence (NICE) and the National Health Service (NHS) England, to partner with Adverum to charter a roadmap for regulatory and development milestones with the goal of early patient access in the United Kingdom (U.K.)

Key Points: 
  • The OPTIC data indicates a greater than 80% reduction in annualized anti-VEGF injections with more than 50% of the trial subjects being supplemental injection-free at two years post-treatment with Ixo-vec, which data is suggestive of a functional cure,” commented Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • “The current standard of care in wet AMD, requires frequent anti-VEGF injections in the eye that can be a lifelong burden for many patients and their caregivers.
  • We believe Ixo-vec has the potential to provide an in-office treatment option that is durable and safe, provides cost-savings, and addresses the needs of wet AMD patients and their families, retina specialists and health systems worldwide.
  • We look forward to leveraging the benefits of ILAP designation, as we continue our development of Ixo-vec.”
    “The ILAP designation grants us enhanced regulatory and market access interactions and a potentially faster path towards approval in the U.K. Ixo-vec has already received Fast Track Designation by the FDA and PRIME designation by the EMA,” said Star Seyedkazemi, PharmD, chief development officer of Adverum Biotechnologies.

Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update

Retrieved on: 
Thursday, March 30, 2023
Maintenance, Adverum Biotechnologies, Anti-VEGF, AMD, Clinical trial, Research, LUNA, Inflammation, Dexamethasone, IVT, Investment, Risk, CST, M.A, R, Three Months, Safety, Pharmaceutical industry, Cryptocurrency, OPTIC

REDWOOD CITY, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on its ongoing Phase 2 LUNA trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet age-related macular degeneration (wet AMD).

Key Points: 
  • I am excited to have enrolled my first subject in the Phase 2 LUNA trial.
  • The Phase 2 LUNA trial evaluating Ixo-vec in subjects with wet AMD continues to enroll.
  • Stock-based compensation expense included in research and development expenses was $1.9 million for the fourth quarter of 2022.
  • Stock-based compensation expense included in general and administrative expenses was $3.3 million for the fourth quarter of 2022.

Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3

Retrieved on: 
Thursday, February 2, 2023
Research, Pharmaceutical, Oncology, Infectious Diseases, Genetics, Clinical Trials, Science, Biotechnology, Neurology, FDA, Health, Diabetes, CER, Arrowhead Pharmaceuticals, Lupus, Major depressive disorder, Safety, Acquisition, ADHD, Fibrosis, Lung cancer, National Medical Products Administration, Multiple myeloma, Psoriasis, Neuroscience, Psoriatic arthritis, PDT, Biologics license application, PP&E, Lymphoma, YTD, Takeda, Growth, Fever Dream, OPTIC, NMPA, Hypovolemia, European Commission, AURORA, VEGFR, Investment, Inflammatory bowel disease, Cytomegalovirus, Civil service commission, Patient, Hereditary angioedema, Therapy, Liver disease, EC, Infection, U.S. FDA, CMV, Primary immunodeficiency, TYK2, ADAMTS13, Hand, Ulcerative colitis, SEQUOIA, Emerging market, Toll, Narcolepsy, USD, Disease, PP, Pharmaceutical industry, Leukemia, Hypoalbuminemia, F4, EU

Growth in our key business areas in FY2022 Q3 YTD was driven largely by Growth & Launch Products1, which delivered reported revenue of 1,199.6 billion yen, marking a +20% increase on a CER basis.

Key Points: 
  • Growth in our key business areas in FY2022 Q3 YTD was driven largely by Growth & Launch Products1, which delivered reported revenue of 1,199.6 billion yen, marking a +20% increase on a CER basis.
  • Sales of TAKHZYRO® (for hereditary angioedema) grew +25% on a CER basis due to expansion of the prophylactic market, continued geographic expansion and strong patient uptake.
  • Plasma-Derived Therapies (PDT) Immunology, with 502.4 billion yen in reported revenue, delivered outstanding growth of +18% on a CER basis.
  • Takeda has continued to deliver on its ability to bring new therapies to patients and capitalize on momentum within its innovative pipeline.

ThinkOn Appoints Technology Innovation and Security Expert Paul West to Lead Global Public Sector Team

Retrieved on: 
Wednesday, January 25, 2023
Cloud, Public sector, Intelligence Committee, Government of Canada, Education, Canadian Centre for Cyber Security, Software, Department of National Defence (Canada), National Security and Intelligence Committee of Parliamentarians, Government, Motorola, Telecommunication, Intelligence, OPTIC, CSP, National security, Bell Canada, Kigali Innovation City, First, Organization, Knowledge, Pension fund, Cryptocurrency, Oil

ETOBICOKE, Ontario, Jan. 25, 2023 (GLOBE NEWSWIRE) -- ThinkOn Inc., a Canadian-based cloud solution provider with a global data centre footprint, is pleased to announce its appointment of Paul West as Director, Global Public Sector.

Key Points: 
  • ETOBICOKE, Ontario, Jan. 25, 2023 (GLOBE NEWSWIRE) -- ThinkOn Inc., a Canadian-based cloud solution provider with a global data centre footprint, is pleased to announce its appointment of Paul West as Director, Global Public Sector.
  • West, who has three decades of experience in cyber security and technology innovation for the public services sector, now leads a team responsible for delivering ThinkOn’s Canadian Sovereign Cloud, Digital Public Safety Network and highly secure solutions that guarantee data supply chain sovereignty for government data.
  • “This is an opportunity to continue my life’s work to encourage tech innovation and secure public sector data governance for Canadians.
  • By offering Canadian-made data solutions, designed for Canadian public sector organizations, West and his team are dedicated to helping Canadian data thrive under the safest conditions possible.

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)

Retrieved on: 
Wednesday, November 16, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Inflammatory bowel disease, Clinical trial, Friends, Diplopia, Cell, TED, Menstrual disorder, Headache, Autoantibody, Safety, Disease, Hair, Huber loss, Breathe Me, Fibroblast, European Group, Week, Partnership, PMDA, Science, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hyperglycemia, Pain, Grit, COVID-19, Health, Hope, Diarrhea, Incidence, Patient, FDA, Trial of the century, Blood pressure, Pressure, Autoimmunity, Spasm, Swelling, Medicines and Healthcare products Regulatory Agency, Cover My Eyes (Pain and Heaven), Red, Graves' ophthalmopathy, Diabetes, Food, Fatigue, Courage, Tachycardia, Medicine, Myalgia, OPTIC, Inflammation, Nausea, Exophthalmos, Family, IBD, Pharmaceutical industry, Silviculture, Medical device, Medical imaging, Birth control, Dysgeusia

With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.

Key Points: 
  • With this trial, we hope to explore the role that TEPEZZA could have for Japanese patients struggling with active Thyroid Eye Disease.
  • The trial methodology is based on the OPTIC Phase 3 trial conducted in the United States and Europe.
  • We are so grateful for the participation and partnership of those living with Thyroid Eye Disease in Japan and our principal investigators, said Elizabeth H.Z.
  • The need for a non-surgical, non-steroidal treatment option for Thyroid Eye Disease in Japan is significant.

Adverum Biotechnologies Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Quality of life, GLOBE, Private Securities Litigation Reform Act, NAMD, Prevalence, Investment, Gene therapy of the human retina, Annual general meeting, Food, Nasdaq, Research, Society, Incidence, Injection, Technology, IRF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neovascularization, Severe cognitive impairment, SEC, NASDAQ, American Academy, Patient, AMD, Macular degeneration, Safety, Compliance, U.S. Securities and Exchange Commission, Caregiver, OPTIC, VEGF, Home After Three Months Away, Retina, Standard of care, European Medicines Agency, Drug discovery, SRF, IVT, Pharmaceutical industry, Birth control, Vaccine, Adverum Biotechnologies

REDWOOD CITY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the third quarter ended September 30, 2022.

Key Points: 
  • In July 2022, Adverum completed an Investigational New Drug amendment with the U.S. Food and Drug Administration to advance a Phase 2 trial of Ixo-vec in wet AMD.
  • Stock-based compensation expense included in research and development expenses was $1.4 million for the third quarter of 2022.
  • Stock-based compensation expense included in general and administrative expenses was $3.1 million for the third quarter of 2022.
  • Additional risks and uncertainties facing Adverum are set forth under the caption Risk Factors and elsewhere in Adverums Securities and Exchange Commission (SEC) filings and reports, including Adverums Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 11, 2022.